Physician profile
Frederick Harada
NPI 1144313875
$6,144.84
in general payments reported to CMS, 2019-2025
19 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $119 · 2021: $84.76 · 2022: $1,202 · 2023: $1,556 · 2024: $1,127 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,309.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $668.90 | 2022-2025 | Adbry, Anzupgo |
| Abbvie INC. | $635.90 | 2019-2025 | |
| Genzyme Corporation | $579.07 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $532.80 | 2019-2025 | Ilumya |
| Arcutis Biotherapeutics, INC. | $488.87 | 2023-2025 | Zoryve |
| Incyte Corporation | $481.06 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $432.51 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Lilly USA, LLC | $404.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $285.40 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $277.87 | 2019-2025 | |
| Ucb, INC. | $260.61 | 2021-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $249.67 | 2019-2023 | Dupixent |
| Galderma Laboratories, L.P. | $186.11 | 2019-2025 | Nemluvio |
| Pfizer INC. | $180.06 | 2022-2023 | |
| Genentech USA, INC. | $162.00 | 2019-2025 | Xolair |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $154.26 | 2023-2024 | Vtama |
| Organon LLC | $61.38 | 2025 | Vtama |
| Dermira, INC. | $52.87 | 2019 | |
| Amgen INC. | $51.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.